{"id":7196,"date":"2025-11-06T17:26:18","date_gmt":"2025-11-06T17:26:18","guid":{"rendered":"https:\/\/wpinitiate.com\/echo-test\/demo973e36f5\/2025\/11\/06\/trump-to-announce-lower-prices-for-weight-loss-drugs-expanded-medicare-eligibility-new-york-post\/"},"modified":"2025-11-06T17:26:18","modified_gmt":"2025-11-06T17:26:18","slug":"trump-to-announce-lower-prices-for-weight-loss-drugs-expanded-medicare-eligibility-new-york-post","status":"publish","type":"post","link":"https:\/\/wpinitiate.com\/echo-test\/demo973e36f5\/2025\/11\/06\/trump-to-announce-lower-prices-for-weight-loss-drugs-expanded-medicare-eligibility-new-york-post\/","title":{"rendered":"Trump to announce lower prices for weight-loss drugs, expanded Medicare eligibility – New York Post"},"content":{"rendered":"
\n

WASHINGTON \u2014 President Trump will announce later Thursday that two major pharmaceutical companies will be lowering the cost of GLP-1\u00a0drugs used to treat diabetes and for weight loss \u2014 and that the government will, in turn, expand eligibility for Medicare users.<\/p>\n

Denmark-based Novo Nordisk, which makes Ozempic, Rybelsus and Wegovy; and Indianapolis-based Eli Lilly, which makes Zepbound, will agree to sell their drugs to Medicare at a lower \u201cmost favored nation\u201d rate, as well as offer discounts direct to other consumers on the TrumpRx website<\/a> that will launch in early 2026, officials said.<\/p>\n

The agreements are the latest in a string of similar deals with drugmakers to avert Trump\u2019s threat of 200% tariffs<\/a> on the industry as the president pushes to return manufacturing to the US.<\/p>\n

\"President
President Trump will announce a deal to lower the cost of popular drugs to treat diabetes and obesity. AP<\/span><\/figcaption><\/figure>\n

The announcement also comes as affordability issues top voter concerns<\/a> ahead of next year\u2019s midterm elections \u2014 with Republicans trounced in New Jersey and Virginia gubernatorial races due to the issue, according to exit polls.<\/p>\n

In exchange for dropping prices on the popular drugs, authorities are relaxing eligibility rules for senior citizens on government-run Medicare programs \u2014 including covering prescriptions of weight-loss drugs alone for people who are severely overweight and expanding comorbidity requirements for others.<\/p>\n

The roughly two-thirds of Americans who are covered by private health insurance also stand to benefit, officials said.<\/p>\n

\u201cThe commercial insurers will also be able to access lower prices, we estimate at least 25% lower than the current cash price market today,\u201d one administration official told reporters on a White House-organized call ahead of Trump\u2019s remarks.<\/p>\n

\u201cWhat we are observing is, in some instances, insurers are beginning to enable beneficiaries to purchase or pay their members to make purchases through the cash market, and then have that count toward their deductible and out-of-pocket maximum.\u201d<\/p>\n

Administration officials presented the agreement as a win-win.<\/p>\n

\"Person
The costs will be dramatically reduced in exchange for expanded Medicare eligibility. russell102 \u2013 stock.adobe.com<\/span><\/figcaption><\/figure>\n

\u201cCompanies here are getting a few things. One is certainty around tariff issues \u2026 That\u2019s one piece. We\u2019re also getting certainty in terms of the administration\u2019s approach to drug pricing,\u201d one official said.<\/p>\n

\u201cIn this particular case, we\u2019re providing additional access to beneficiaries who wouldn\u2019t otherwise be covered by Medicare for obesity indications, and so there\u2019s access to additional patients who could really benefit from these medications, and that\u2019s mutually beneficial for both the taxpayer, for those beneficiaries, as well as for the companies. Over the long term, our expectation is that this will be cost neutral.\u201d<\/p>\n

\n
\n

\t\t\t\t\t\t\tStart your day with all you need to know\t\t\t\t\t\t<\/h3>\n

\t\t\t\t\t\t\tMorning Report delivers the latest news, videos, photos and more.\t\t\t\t\t\t<\/p>\n<\/p><\/div>\n

\t\t\t\t\t\tThanks for signing up!\t\t\t\t\t<\/h3>\n<\/p><\/div>\n

The drug costs will gradually be lowered under the plan.<\/p>\n

\u201cOn TrumpRX, the average price of injectables \u2026 will be at or below $350 to start. This compares to $500 roughly today. That will trend down to the same $245 over 24 months,\u201d an official said, with under-development oral medications, should they be approved, starting at $149.<\/p>\n

The co-pay for Medicare beneficiaries will be $50.<\/p>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"

WASHINGTON \u2014 President Trump will announce later Thursday that two major pharmaceutical companies will be lowering the cost of GLP-1\u00a0drugs used to treat diabetes and for weight loss \u2014 and that the government will, in turn, expand eligibility for Medicare users. Denmark-based Novo Nordisk, which makes Ozempic, Rybelsus and Wegovy; and Indianapolis-based Eli Lilly, which […]<\/p>\n","protected":false},"author":1,"featured_media":7197,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-7196","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/wpinitiate.com\/echo-test\/demo973e36f5\/wp-json\/wp\/v2\/posts\/7196","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wpinitiate.com\/echo-test\/demo973e36f5\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wpinitiate.com\/echo-test\/demo973e36f5\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wpinitiate.com\/echo-test\/demo973e36f5\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/wpinitiate.com\/echo-test\/demo973e36f5\/wp-json\/wp\/v2\/comments?post=7196"}],"version-history":[{"count":0,"href":"https:\/\/wpinitiate.com\/echo-test\/demo973e36f5\/wp-json\/wp\/v2\/posts\/7196\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wpinitiate.com\/echo-test\/demo973e36f5\/wp-json\/wp\/v2\/media\/7197"}],"wp:attachment":[{"href":"https:\/\/wpinitiate.com\/echo-test\/demo973e36f5\/wp-json\/wp\/v2\/media?parent=7196"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wpinitiate.com\/echo-test\/demo973e36f5\/wp-json\/wp\/v2\/categories?post=7196"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wpinitiate.com\/echo-test\/demo973e36f5\/wp-json\/wp\/v2\/tags?post=7196"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}